<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874610</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00108152</org_study_id>
    <nct_id>NCT04874610</nct_id>
  </id_info>
  <brief_title>Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus</brief_title>
  <official_title>Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, open-label, non-randomized study to assess the pharmacokinetic profile of&#xD;
      methylprednisolone in healthy children 2-20 years of age admitted for asthma exacerbation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study aiming to characterize the pharmacokinetics of methylprednisolone&#xD;
      in obese and non-obese children hospitalized for asthma, and to build a metabolomic profile&#xD;
      for each cohort. The primary hypothesis is that the obese cohort will have increased&#xD;
      methylprednisolone clearance compared to the non-obese cohort. The secondary hypothesis is&#xD;
      that the obese cohort will have decreased amounts of 11-Î²-hydroxysteroid dehydrogenase in the&#xD;
      serum which will correlate to abnormalities in steroid clearance. The tertiary hypothesis is&#xD;
      that the obese cohort will have increased levels of branched chain amino acids and&#xD;
      inflammatory markers which will correlate to disease severity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Prednisolone concentration levels as measured by ELISA</measure>
    <time_frame>0, 24, 48, 72, 96 hours after methylprednisolone dosing</time_frame>
    <description>Prednisolone levels at steady state concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>11-beta-hydroxysteroid dehydrogenase as measured by ELISA</measure>
    <time_frame>Up to 72 hours after methylprednisolone dosing</time_frame>
    <description>11-beta-hydroxysteroid dehydrogenase levels</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pediatric Obesity</condition>
  <condition>Asthma in Children</condition>
  <arm_group>
    <arm_group_label>BMI &gt; 95</arm_group_label>
    <description>Cohort 1: greater than or equal to 95%ile body mass index</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &lt; 95</arm_group_label>
    <description>Cohort 2: less than 95%ile body mass index</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Administration of methylprednisolone Prescribed per Standard of care</description>
    <arm_group_label>BMI &lt; 95</arm_group_label>
    <arm_group_label>BMI &gt; 95</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma from blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children and young adults 2-20 years of age who are admitted to Duke Hospital for primary&#xD;
        reason of asthma exacerbation and are treated with methylprednisolone.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 2 years and 20 years inclusive&#xD;
&#xD;
          2. Written informed consent provided by a parent or legal guardian&#xD;
&#xD;
          3. Admitted to Duke Children's Hospital for primary reason of asthma exacerbation (and&#xD;
             treated with methylprednisolone)&#xD;
&#xD;
          4. BMI-percentile greater than 95th for obese subjects and BMI less than 95th percentile&#xD;
             for non-obese subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with suspected liver failure, renal failure, sepsis, or cardiopulmonary&#xD;
             instability deemed by the PI.&#xD;
&#xD;
          2. Receiving any extracorporeal life support including extracorporeal membrane&#xD;
             oxygenation, ventricular assist devices, and renal replacement therapy at enrollment&#xD;
&#xD;
          3. Any condition or circumstance that, in the opinion of the investigator, would&#xD;
             compromise the safety of the participant or the quality of the data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Caitlin King, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caitlin King, MD</last_name>
    <phone>501-499-5161</phone>
    <email>caitlin.king@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Lang, MD</last_name>
    <email>jason.lang@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin King, MD</last_name>
      <phone>501-499-5161</phone>
      <email>caitlin.king@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jason Lang, MD</last_name>
      <email>jason.lang@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Caitlin King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Lang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Asthmaticus</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

